Lucia Di Nardo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucia Di Nardo has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
- Ketty Peris
Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy
15 shared publications - Maria Concetta Fargnoli
San Gallicano Dermatological Institute-IRCCS, Rome, Italy
9 shared publications - Andrea Chiricozzi
Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
8 shared publications - Cristina Pellegrini
Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
8 shared publications - Alessandro Di Stefani
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale Università Cattolica del Sacro Cuore Rome Italy
5 shared publications Laura Del Regno
5 shared publications
Latest Publications
- 2 April 2026
- Published by S. Karger AG in Dermatology
- Vol. 242 (4) , 1-8
Clinical and Histopathological Predictors of Disease Progression in Stage II Cutaneous Melanoma
Introduction: The recent approval of pembrolizumab and nivolumab for the adjuvant treatment of stage IIB–IIC cutaneous melanoma (CM) significantly improved the relapse-free survival probability of this patient population. Real-life data suggest that not all stage IIB and IIC CM patients will invariably undergo disease progression. There is a growing need for accurate patients’ selection for whom adjuvant therapy is expected to be beneficial. The aim of this study was to investigate the baseline clinical and histopathological features associated with tumor recurrence in stage II CM patients in an Italian tertiary referral center. Methods: Patients’ clinical features and histopathological tumor characteristics were recorded at the time of melanoma diagnosis. Non-recurrent patients were defined based on a ≥5-year follow-up period; time to disease recurrence was calculated as the time from the diagnosis of the primary tumor until first evidence of melanoma relapse. Results: A total of 103 stage II CM patients, with a median follow-up of 6.2 years, were included. Twenty-one of 103 (20.4%) patients recurred, of whom 15/21 (71.4%) showed disease progression to stage IV disease. Breslow thickness was significantly associated with CM recurrence, with a 70% increased probability of melanoma relapse per each unit increase in Breslow thickness (mm) (OR = 1.7; 95% CI: 1.05–2.7; p = 0.029). Histopathological evidence of ulceration and the mitotic rate did not show a significant association with melanoma progression. Breslow thickness was also associated with a reduced time from melanoma diagnosis to recurrence per each unit increase (mm) (p = 0.032) and with shorter disease-free survival probability (HR: 1.47; 95% CI: 1.05–2.06; p = 0.025). Conclusion: Breslow thickness is a relevant prognostic factor for CM recurrence. Further studies are needed to identify novel prognostic biomarkers.
- 2 April 2026
- Published by S. Karger AG in Dermatology
- Vol. 242 (4) , 1-8
Clinical and Histopathological Predictors of Disease Progression in Stage II Cutaneous Melanoma
Introduction: The recent approval of pembrolizumab and nivolumab for the adjuvant treatment of stage IIB–IIC cutaneous melanoma (CM) significantly improved the relapse-free survival probability of this patient population. Real-life data suggest that not all stage IIB and IIC CM patients will invariably undergo disease progression. There is a growing need for accurate patients’ selection for whom adjuvant therapy is expected to be beneficial. The aim of this study was to investigate the baseline clinical and histopathological features associated with tumor recurrence in stage II CM patients in an Italian tertiary referral center. Methods: Patients’ clinical features and histopathological tumor characteristics were recorded at the time of melanoma diagnosis. Non-recurrent patients were defined based on a ≥5-year follow-up period; time to disease recurrence was calculated as the time from the diagnosis of the primary tumor until first evidence of melanoma relapse. Results: A total of 103 stage II CM patients, with a median follow-up of 6.2 years, were included. Twenty-one of 103 (20.4%) patients recurred, of whom 15/21 (71.4%) showed disease progression to stage IV disease. Breslow thickness was significantly associated with CM recurrence, with a 70% increased probability of melanoma relapse per each unit increase in Breslow thickness (mm) (OR = 1.7; 95% CI: 1.05–2.7; p = 0.029). Histopathological evidence of ulceration and the mitotic rate did not show a significant association with melanoma progression. Breslow thickness was also associated with a reduced time from melanoma diagnosis to recurrence per each unit increase (mm) (p = 0.032) and with shorter disease-free survival probability (HR: 1.47; 95% CI: 1.05–2.06; p = 0.025). Conclusion: Breslow thickness is a relevant prognostic factor for CM recurrence. Further studies are needed to identify novel prognostic biomarkers.
- 20 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (5)
Pregnancy‐associated melanoma: A distinct entity requiring vigilance
- 20 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (5)
Pregnancy‐associated melanoma: A distinct entity requiring vigilance
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 8309058
Neutrophil‐to‐Lymphocyte Ratio Dynamics and Progression‐Free Survival in Advanced Cutaneous Squamous Cell Carcinoma Treated With Cemiplimab
Background: Patients with locally advanced (la) and metastatic (m) cutaneous squamous cell carcinoma (CSCC) for which curative surgery or radiation is not available may benefit from treatment with anti–programmed cell death 1 (PD‐1) monoclonal antibody cemiplimab. The predictive and prognostic role of hematological markers in such patients remains unclear. Type of Study: A real‐life retrospective cohort study was conducted to evaluate the role of hematological inflammatory parameters as predictive and prognostic factors in patients with laCSCC and mCSCC who underwent first‐line treatment with cemiplimab. Methods: Lymphocyte–monocyte ratio (LMR), neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), albumin, creatinine, systemic immune–inflammation index (SII), and LDH were measured prior to cemiplimab therapy and subsequently at the first follow‐up visit. To evaluate independent prognostic factors, the 12‐month time‐dependent performance was assessed using the incident/dynamic receiver operating characteristic (ROC) framework implemented with a nearest‐neighbor estimator. Model performance metrics, including Harrell’s C‐index and the time‐dependent area under the curve (AUC), were quantified with 95% confidence intervals. Results: A total of 43 CSCC patients including 37 (86.1%) with laCSCC and 6 (14.0%) with mCSCC were retrospectively enrolled. After a median of 33.1 weeks (8.4 months) of exposure to cemiplimab, ORR was 72% (31/43), including 41.9% (13/31) complete responses and 58.1% (18/31) partial responses; stable disease was observed in 9.7% (3/31). The median progression‐free survival (PFS) was 6.4 months (IQR, 3.9–14.7 months). Overall, 7% of patients discontinued therapy due to adverse events (Grade 3 renal insufficiency and liver toxicity). We identified a significant inverse association between NLR change from baseline to first on‐treatment visit (ΔNLR) and PFS (Coeff = −0.25; 95% CI [jackknife] = −0.45–0.05, p = 0.014), showing higher ΔNLR score in patients with shorter PFS. The ΔNLR was associated with a 36% higher chance of progression (HR = 1.36, 95% CI = 0.97–1.89, p = 0.073), adjusted for age, systemic inflammatory index, and sex. Decision curve analysis showed a modest net benefit of the ΔNLR‐based model across a broad range of threshold probabilities (approximately 7%–49%), without identification of a clinically optimal decision threshold. Conclusion: Our study suggests that ΔNLR may serve as an exploratory prognostic indicator in patients with laCSCC and mCSCC.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 8309058
Open AccessNeutrophil‐to‐Lymphocyte Ratio Dynamics and Progression‐Free Survival in Advanced Cutaneous Squamous Cell Carcinoma Treated With Cemiplimab
Background: Patients with locally advanced (la) and metastatic (m) cutaneous squamous cell carcinoma (CSCC) for which curative surgery or radiation is not available may benefit from treatment with anti–programmed cell death 1 (PD‐1) monoclonal antibody cemiplimab. The predictive and prognostic role of hematological markers in such patients remains unclear. Type of Study: A real‐life retrospective cohort study was conducted to evaluate the role of hematological inflammatory parameters as predictive and prognostic factors in patients with laCSCC and mCSCC who underwent first‐line treatment with cemiplimab. Methods: Lymphocyte–monocyte ratio (LMR), neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), albumin, creatinine, systemic immune–inflammation index (SII), and LDH were measured prior to cemiplimab therapy and subsequently at the first follow‐up visit. To evaluate independent prognostic factors, the 12‐month time‐dependent performance was assessed using the incident/dynamic receiver operating characteristic (ROC) framework implemented with a nearest‐neighbor estimator. Model performance metrics, including Harrell’s C‐index and the time‐dependent area under the curve (AUC), were quantified with 95% confidence intervals. Results: A total of 43 CSCC patients including 37 (86.1%) with laCSCC and 6 (14.0%) with mCSCC were retrospectively enrolled. After a median of 33.1 weeks (8.4 months) of exposure to cemiplimab, ORR was 72% (31/43), including 41.9% (13/31) complete responses and 58.1% (18/31) partial responses; stable disease was observed in 9.7% (3/31). The median progression‐free survival (PFS) was 6.4 months (IQR, 3.9–14.7 months). Overall, 7% of patients discontinued therapy due to adverse events (Grade 3 renal insufficiency and liver toxicity). We identified a significant inverse association between NLR change from baseline to first on‐treatment visit (ΔNLR) and PFS (Coeff = −0.25; 95% CI [jackknife] = −0.45–0.05, p = 0.014), showing higher ΔNLR score in patients with shorter PFS. The ΔNLR was associated with a 36% higher chance of progression (HR = 1.36, 95% CI = 0.97–1.89, p = 0.073), adjusted for age, systemic inflammatory index, and sex. Decision curve analysis showed a modest net benefit of the ΔNLR‐based model across a broad range of threshold probabilities (approximately 7%–49%), without identification of a clinically optimal decision threshold. Conclusion: Our study suggests that ΔNLR may serve as an exploratory prognostic indicator in patients with laCSCC and mCSCC.
- 24 October 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (5) , 835-840
Pregnancy‐associated melanoma epidemiology: A multicentre European study
Background: Melanoma is the most common malignancy during pregnancy, with incidence rates rising globally. While most studies focus on prognosis, limited data exist on melanoma in the early post‐partum period. Objectives: This multicentre European study aimed to characterize the epidemiologic and clinicopathologic features of pregnancy‐associated melanoma (PAM) and assess whether these tumours differ from melanomas not associated with pregnancy. Methods: We identified 1,270 women of reproductive age (15–49 years) diagnosed with melanoma between 2012 and 2022 across six melanoma centres in five European countries. Results: Among them, 70 cases (5.5%) were classified as PAM (range: 1.2%–14.3%). Compared to non‐PAM patients, women with PAM were younger (mean age 35.7 years; p < 0.001) and more likely to have a high nevus count ( p = 0.031). The majority of PAMs (80.0%) were superficial spreading, and mean Breslow thickness was 1.16 mm; 12.9% were ulcerated. Notably, 57.1% developed on a pre‐existing nevus. Histopathologic features were similar between groups, except for tumour‐infiltrating lymphocytes (TILs): non‐PAM tumours exhibited significantly more dense TILs ( p = 0.012), possibly indicating a stronger immune response. Median follow‐up was 5.5 years. Recurrence‐free survival did not significantly differ between groups; the 5‐year recurrence‐free survival rate was 95%. Conclusions: Although pregnancy does not appear to adversely impact melanoma prognosis, PAM demonstrates some distinct clinical features that warrant further investigation given the fact that it affects a substantial proportion of women of reproductive age diagnosed with melanoma. The frequent occurrence of PAM on pre‐existing nevi highlights the importance of raising public awareness and promoting dermatologic evaluation of suspicious lesions during pregnancy.
- 24 October 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (5) , 835-840
Pregnancy‐associated melanoma epidemiology: A multicentre European study
Background: Melanoma is the most common malignancy during pregnancy, with incidence rates rising globally. While most studies focus on prognosis, limited data exist on melanoma in the early post‐partum period. Objectives: This multicentre European study aimed to characterize the epidemiologic and clinicopathologic features of pregnancy‐associated melanoma (PAM) and assess whether these tumours differ from melanomas not associated with pregnancy. Methods: We identified 1,270 women of reproductive age (15–49 years) diagnosed with melanoma between 2012 and 2022 across six melanoma centres in five European countries. Results: Among them, 70 cases (5.5%) were classified as PAM (range: 1.2%–14.3%). Compared to non‐PAM patients, women with PAM were younger (mean age 35.7 years; p < 0.001) and more likely to have a high nevus count ( p = 0.031). The majority of PAMs (80.0%) were superficial spreading, and mean Breslow thickness was 1.16 mm; 12.9% were ulcerated. Notably, 57.1% developed on a pre‐existing nevus. Histopathologic features were similar between groups, except for tumour‐infiltrating lymphocytes (TILs): non‐PAM tumours exhibited significantly more dense TILs ( p = 0.012), possibly indicating a stronger immune response. Median follow‐up was 5.5 years. Recurrence‐free survival did not significantly differ between groups; the 5‐year recurrence‐free survival rate was 95%. Conclusions: Although pregnancy does not appear to adversely impact melanoma prognosis, PAM demonstrates some distinct clinical features that warrant further investigation given the fact that it affects a substantial proportion of women of reproductive age diagnosed with melanoma. The frequent occurrence of PAM on pre‐existing nevi highlights the importance of raising public awareness and promoting dermatologic evaluation of suspicious lesions during pregnancy.
- 3 February 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (6)
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis
- 3 February 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (6)
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis
- Open Access
- 14 November 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (4) , 647-653
Wound closure techniques after wide excision for hidradenitis suppurativa: a systematic review and meta‐analysis
Hidradenitis suppurativa (HS) is a chronic inflammatory disease that affects intertriginous skin areas, clinically characterized by recurrent inflamed nodules, abscesses, sinus tracts, and severe scars. Systemic treatments may provide temporary relief, while wide surgical excision offers prolonged disease‐free periods. We evaluated the most efficient wound closure methods following wide excision of HS lesions in terms of recurrence, functionality, and quality of life. A systematic literature search was conducted in PubMed, Embase, Cochrane, and ClinicalTrials.gov , adhering to the PRISMA 2020 criteria. We included original studies published until February 2024, focusing on wound closure methods post‐wide excision for HS. Data from 121 papers were analyzed using network and direct meta‐analysis methods to compare recurrence and postoperative complication rates. From 1181 articles, 121 were included in the meta‐analysis after removing duplicates and excluding publications that did not meet the inclusion criteria. Recurrence rates were associated with the type of reconstruction technique as follows: primary closure, 25% (95% confidence interval [CI], 20–30%); skin grafts, 18% (95% CI, 14–22%), and flaps, 12% (95% CI, 9–15%). Secondary intention healing showed a recurrence rate of 28% (95% CI, 23–33%). Flaps were associated with the lowest recurrence rates compared to other surgery techniques.
- 14 November 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (4) , 647-653
Open AccessWound closure techniques after wide excision for hidradenitis suppurativa: a systematic review and meta‐analysis
Hidradenitis suppurativa (HS) is a chronic inflammatory disease that affects intertriginous skin areas, clinically characterized by recurrent inflamed nodules, abscesses, sinus tracts, and severe scars. Systemic treatments may provide temporary relief, while wide surgical excision offers prolonged disease‐free periods. We evaluated the most efficient wound closure methods following wide excision of HS lesions in terms of recurrence, functionality, and quality of life. A systematic literature search was conducted in PubMed, Embase, Cochrane, and ClinicalTrials.gov , adhering to the PRISMA 2020 criteria. We included original studies published until February 2024, focusing on wound closure methods post‐wide excision for HS. Data from 121 papers were analyzed using network and direct meta‐analysis methods to compare recurrence and postoperative complication rates. From 1181 articles, 121 were included in the meta‐analysis after removing duplicates and excluding publications that did not meet the inclusion criteria. Recurrence rates were associated with the type of reconstruction technique as follows: primary closure, 25% (95% confidence interval [CI], 20–30%); skin grafts, 18% (95% CI, 14–22%), and flaps, 12% (95% CI, 9–15%). Secondary intention healing showed a recurrence rate of 28% (95% CI, 23–33%). Flaps were associated with the lowest recurrence rates compared to other surgery techniques.
- Open Access
- 30 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3864
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study
Background: Psoriatic disease, a chronic immune-mediated systemic inflammatory condition, significantly impairs patients’ quality of life. The advent of highly targeted biological therapies has transformed treatment strategies, emphasizing the importance of selecting the most effective and cost-efficient option. Secukinumab, an IL-17A inhibitor, has demonstrated efficacy and safety in treating moderate-to-severe plaque psoriasis (PsO). However, long-term real-world data on its effectiveness and persistence rate are limited. Methods: This retrospective study, conducted across eight Italian dermatology centers, aimed to evaluate the 6-year persistence rate and effectiveness of secukinumab in patients with PsO. Additionally, the study investigated the onset of psoriatic arthritis during treatment. Results: Overall, 166 adult patients were analyzed. Their median age was 53.9 years. The mean BMI was 26.5. Of the 166 patients, 64 were bio-experienced while 102 were bio-naïve. A progressive reduction in PsO severity measured by PASI scores over 6 years of treatment was revealed: the PASI score decreased from a baseline value of 18.1 (±9.1) to 0.7 (±1.6) after 6 years of follow-up. Adverse events, including mucocutaneous fungal infections and cardiovascular disturbances, were reported in 19.9% of patients. The persistence rate was 86.8% at 24 months, decreasing to 66.4% at 72 months. Psoriatic arthritis onset during treatment was observed in 15 (9.0%) of patients. Conclusions: This study highlights the sustained effectiveness and favorable safety profile of secukinumab over 6 years, providing valuable real-world evidence. Understanding the long-term persistence rate and predictors of discontinuation could help clinicians optimize treatment decisions and improve patient outcomes in PsO management. We found that the absence of scalp PsO, no involvement of the genital area and normal weight were the best factors of persistence in secukinumab treatment in the long term.
- 30 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3864
Open AccessLong-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study
Background: Psoriatic disease, a chronic immune-mediated systemic inflammatory condition, significantly impairs patients’ quality of life. The advent of highly targeted biological therapies has transformed treatment strategies, emphasizing the importance of selecting the most effective and cost-efficient option. Secukinumab, an IL-17A inhibitor, has demonstrated efficacy and safety in treating moderate-to-severe plaque psoriasis (PsO). However, long-term real-world data on its effectiveness and persistence rate are limited. Methods: This retrospective study, conducted across eight Italian dermatology centers, aimed to evaluate the 6-year persistence rate and effectiveness of secukinumab in patients with PsO. Additionally, the study investigated the onset of psoriatic arthritis during treatment. Results: Overall, 166 adult patients were analyzed. Their median age was 53.9 years. The mean BMI was 26.5. Of the 166 patients, 64 were bio-experienced while 102 were bio-naïve. A progressive reduction in PsO severity measured by PASI scores over 6 years of treatment was revealed: the PASI score decreased from a baseline value of 18.1 (±9.1) to 0.7 (±1.6) after 6 years of follow-up. Adverse events, including mucocutaneous fungal infections and cardiovascular disturbances, were reported in 19.9% of patients. The persistence rate was 86.8% at 24 months, decreasing to 66.4% at 72 months. Psoriatic arthritis onset during treatment was observed in 15 (9.0%) of patients. Conclusions: This study highlights the sustained effectiveness and favorable safety profile of secukinumab over 6 years, providing valuable real-world evidence. Understanding the long-term persistence rate and predictors of discontinuation could help clinicians optimize treatment decisions and improve patient outcomes in PsO management. We found that the absence of scalp PsO, no involvement of the genital area and normal weight were the best factors of persistence in secukinumab treatment in the long term.
- 27 March 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (10) , e892-e895
Long‐term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real‐world retrospective study
- 27 March 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (10) , e892-e895
Long‐term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real‐world retrospective study
- 29 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (10) , e852-e854
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series
- 29 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (10) , e852-e854
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series
- Open Access
- 31 January 2024
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 14 (1) , e2024028
Confocal Assessment of Pigmented-Mucosal Lesions: A Monocentric, Retrospective Evaluation of Lip and Genital Area
Introduction: Pigmentation of lip and/or genitalia is mainly due to the development of benign melanotic macules, with a less occurrence of melanocytic and other non-melanocytic lesions. Mucosal melanoma has worse prognosis compared with cutaneous counterpart, hence identification of atypical features for an early diagnosis is crucial. Objectives: The aim of this study was to report further data of confocal features characterizing pigmented mucosal lesions of genital area and of the lips and test the diagnostic role of the reflectance confocal microscopy (RCM)lip score. Methods: Clinical, dermoscopic and RCM images of histologically proven pigmented lesions, involving the genital area (vulva or glans penis) and lip, were retrospectively reviewed. RCM images were evaluated for malignant criteria, and statistical analysis was conducted for categorical variables. Results: Seventy pigmented lesions were included in the study and divided into two groups based on the body area location: lip (17) and genital area (53). Architectural disarray (P = 0.002), dendritic (P = 0.031) and roundish cells in epidermis (P < 0.0001), interpapillary dendritic cells (P = 0.039) and junctional atypical cells (P = 0.002) were associated to genital melanoma. Melanoma involving the lip was characterized by roundish cells in epidermis, a criterion found in one labial benign lesion, only (P = 0.005). Main limitations of the study are the inclusion of low melanomas and the presence of epidermal dendritic cells in melanosis and melanoma, as a confusing factor in imaging. Conclusions: Dermatologists should consider confocal microscopy as an adjunctive tool to dermoscopy in the differential diagnosis of pigmented mucosal lesions, especially in presence of clinical and dermoscopic findings suspicious for malignancy.
- 31 January 2024
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 14 (1) , e2024028
Open AccessConfocal Assessment of Pigmented-Mucosal Lesions: A Monocentric, Retrospective Evaluation of Lip and Genital Area
Introduction: Pigmentation of lip and/or genitalia is mainly due to the development of benign melanotic macules, with a less occurrence of melanocytic and other non-melanocytic lesions. Mucosal melanoma has worse prognosis compared with cutaneous counterpart, hence identification of atypical features for an early diagnosis is crucial. Objectives: The aim of this study was to report further data of confocal features characterizing pigmented mucosal lesions of genital area and of the lips and test the diagnostic role of the reflectance confocal microscopy (RCM)lip score. Methods: Clinical, dermoscopic and RCM images of histologically proven pigmented lesions, involving the genital area (vulva or glans penis) and lip, were retrospectively reviewed. RCM images were evaluated for malignant criteria, and statistical analysis was conducted for categorical variables. Results: Seventy pigmented lesions were included in the study and divided into two groups based on the body area location: lip (17) and genital area (53). Architectural disarray (P = 0.002), dendritic (P = 0.031) and roundish cells in epidermis (P < 0.0001), interpapillary dendritic cells (P = 0.039) and junctional atypical cells (P = 0.002) were associated to genital melanoma. Melanoma involving the lip was characterized by roundish cells in epidermis, a criterion found in one labial benign lesion, only (P = 0.005). Main limitations of the study are the inclusion of low melanomas and the presence of epidermal dendritic cells in melanosis and melanoma, as a confusing factor in imaging. Conclusions: Dermatologists should consider confocal microscopy as an adjunctive tool to dermoscopy in the differential diagnosis of pigmented mucosal lesions, especially in presence of clinical and dermoscopic findings suspicious for malignancy.